Data / Form D filings / Synereca Pharmaceuticals, Inc.
Synereca Pharmaceuticals, Inc.: Form D filings
Synereca Pharmaceuticals, Inc., a health care company in Oklahoma City, OK, filed 2 Form D notices with the SEC between 2011 and 2017. The latest, on August 15, 2017, reports $600,000 sold of a $1.2 million offering to 10 investors.
Find out what Synereca Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 865 RESEARCH PARKWAY, SUITE 400, Oklahoma City, OK, 73104
- Phone
- (405) 319-8165
- Industry
- Other Health Care
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1487939
The full lists. Form D filings in Oklahoma: 227 rows, $11.35, or the new rows each week for $19 a month. Form D filings in Other Health Care: 1,958 rows, $97.90, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 15, 2017 | New notice | $1,200,000 | $600,000 | $600,000 | 10 | Aug 2, 2017 | sec.gov |
| Feb 8, 2011 | New notice | $340,000 | $300,492 | $39,508 | 7 | Dec 17, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Bennett W. Love | Director | |
| Clayton I. Duncan | Executive Officer, Director | |
| Scott F. Singleton | Director | |
| Mark I. Corrigan | Director | |
| Richard E. Gammans | Executive Officer, Promoter | |
| Scott I. Meacham | Director |
Every Form D from the week of Aug 14, 2017 · All recent filings in Oklahoma · All recent Other Health Care filings
Read from SEC EDGAR. Amount sold is what Synereca Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.